Pharmacokinetics and Metabolism of [14C] BMS-986195 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2018
At a glance
- Drugs BMS 986195 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 03 Jan 2018 Status changed from recruiting to completed.
- 30 Aug 2017 Planned number of patients changed from 8 to 9.
- 30 Aug 2017 Planned End Date changed from 22 Nov 2017 to 21 Nov 2017.